Ozempic, Wegovy, and Mounjaro Gastroparesis (Stomach Paralysis) Lawsuit Lawyers

Ozempic, Wegovy, and Mounjaro have been linked to stomach paralysis & NAION vision loss.

According to Healthline.com, injectable medications Ozempic and Wegovy (active ingredient semaglutide) and Mounjaro (active ingredient tirzepatide), work by slowing down digestion in the stomach. In some instances, this delay in stomach emptying, known as gastroparesis (or “stomach paralysis”) , can occur.

The United States Food & Drug Administration (FDA) has been receiving reports of gastroparesis with semaglutide and liraglutide, with some documenting that the adverse event was unresolved even after the product was discontinued at the time of reporting.

Physicians who specialize in gastroparesis treatment say they are also hearing more reports of gastroparesis as an increasing number of people use these medications.

Free Consultation for Ozempic Side Effects Victims

Parker Waichman LLP understands the challenges faced by individuals who have experienced adverse effects after being prescribed Ozempic. If you or a loved one have suffered from any of the following side effects and injuries associated with Ozempic usage, including gastroparesis, gastroenteritis, delayed gastric emptying, recommended intestinal surgery, pancreatic cancer, intraoperative pulmonary aspiration, deep vein thrombosis, or pulmonary aspiration, our national product liability law firm is here to help. We are offering a free consultation to discuss your legal options and potential compensation for your suffering.

• Gastroparesis;
• Gastroenteritis;
• Vision Loss;
• Non-arteritic Anterior Ischemic Optic Neuropathy (NAION);
• Delayed gastric emptying;
• Intestinal surgery – except for gallbladder surgery;
• Recommended intestinal surgery;
• Pancreatic cancer;
• Intraoperative pulmonary aspiration (must be on medication or within 6 months post stopping drug);
• Suicide attempts;
• Deep vein thrombosis (while on drug);
• Pulmonary Aspiration;
• Non-arteritic anterior ischemic optic neuropathy (NAION); and
• Wet age-related macular degeneration (WetAMD)

Our experienced attorneys are dedicated to advocating for the rights of individuals harmed by dangerous pharmaceuticals. We will carefully evaluate your case, provide personalized legal guidance, and pursue justice on your behalf.

Don’t hesitate to reach out to us to schedule your free consultation and take the first step towards seeking the compensation you deserve. For your free consultation, contact our national product liability law firm today by using our live chat or calling 800-968-7529.

What Victims of Ozempic Should Know

• FDA Approval: Ozempic, Wegovy, and Mounjaro received FDA approval, but the drug makers failed to adequately disclose the risks of severe gastrointestinal events, such as stomach paralysis, associated with these products.
• Extensive Advertising: The drug makers spent millions on advertising, promoting the safety and efficacy of these drugs. The truth about the risks may have been hidden from the public, however.
• Your Rights: If you or someone you love has suffered from adverse effects after taking these drugs, you may be entitled to compensation for medical expenses, lost wages, pain, and suffering.

On March 28, 2022, Novo Nordisk announced the FDA’s approval of a higher (2 mg) dose of the Ozempic (semaglutide) injection. In the press release, the drug maker represented Ozempic as having “proven safety and efficacy” and further advertised that ” it can help many patients lose some weight.” However, severe gastrointestinal events, such as gastroparesis and gastroenteritis, were not identified as risks.

Similarly, on May 13, 2022, Eli Lilly announced FDA approval of Mounjaro (tirzepatide), pitched by the drug maker as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes. In the announcement, Eli Lilly disclosed a safety summary, but severe gastrointestinal events were not identified as risks.

‍2025 JAMA Study Links Vision Loss and Permanent Blindness to Ozempic and Wegovy

Recent studies have linked Ozempic and Wegovy to non-arteritic anterior ischemic optic neuropathy (NAION), a condition that causes permanent vision loss by restricting blood flow to the optic nerve. Patients who took these GLP-1 weight loss and diabetes drugs have reported sudden blindness, optic nerve inflammation, and irreversible damage—life-altering effects that were never properly disclosed by drug manufacturers.

A 2025 JAMA Ophthalmology study revealed that GLP-1 drug users are at a significantly higher risk of developing NAION and other optic nerve disorders. Harvard researchers found that diabetics taking semaglutide were four times more likely to develop NAION, while non-diabetic users taking the drug for weight loss were at a seven times higher risk. Despite this alarming data, Novo Nordisk continues to downplay these risks, failing to provide adequate warnings about the potential for permanent blindness.

EMA Confirms NAION Vision Loss Risk in Ozempic and Wegovy Patients

In September 2025, the European Medicines Agency (EMA) issued a formal warning that Ozempic, Wegovy, and Rybelsus carry a “very rare but serious” risk of causing non-arteritic anterior ischemic optic neuropathy (NAION). NAION is a devastating condition that can lead to irreversible vision loss.

According to the EMA’s updated regulatory language:

“Data from epidemiological studies indicates an increased risk for non-arteritic anterior ischaemic optic neuropathy (NAION) during treatment with semaglutide. There is no identified time interval for when NAION may develop following treatment start. A sudden loss of vision should lead to ophthalmological examination, and treatment with semaglutide should be discontinued if NAION is confirmed.”

This language is now included in the Summary of Product Characteristics (SmPC) and Package Leaflet, formalizing NAION as an adverse event of concern.

The decision came after months of pharmacovigilance review and mounting evidence, including the 2024 Mass Eye and Ear study and 2025 analyses published in JAMA Ophthalmology. These studies found that semaglutide users face a 4.28-fold increased risk of NAION in diabetic patients and a 7.64-fold increased risk in patients using the drugs for weight loss.

Despite the data, U.S. regulators have not issued a comparable warning, leaving American patients at risk. “People trusted that these medications were safe for use,” said Jason Goldstein, Senior Litigation Counsel at Parker Waichman LLP. “This new EMA confirmation underscores what we have been seeing through our clients’ experiences—sudden, devastating loss of vision that changes lives forever.”

Parker Waichman LLP is currently representing patients across the United States who have experienced sudden vision loss, permanent blindness, or non‑arteritic anterior ischemic optic neuropathy (NAION) after using semaglutide medications such as Ozempic, Wegovy, or Rybelsus. Our law firm is actively filing claims across the nation on behalf of individuals who trusted these medications to manage diabetes or assist with weight loss, only to suffer irreversible eye injuries that dramatically altered their lives.

Our legal team is working closely with medical experts, ophthalmologists, and pharmacovigilance specialists to uncover what Novo Nordisk knew about these risks and when the company first became aware of the connection between semaglutide and optic nerve damage. We are pursuing justice for victims whose lives have been disrupted by loss of sight, ensuring that corporate accountability and patient safety remain front and center in this developing litigation.

Filing a Lawsuit for GLP-1 Drug-Related Vision Loss

Victims suffering from vision loss after using Ozempic, Wegovy, or similar medications, may have grounds to file a product liability lawsuit against the manufacturers. These lawsuits allege that drug companies failed to warn users about the risk of optic nerve damage—a serious omission that has left unsuspecting patients with irreversible blindness.

Compensation may cover:

• Medical expenses for treatment and vision therapy
• Lost wages due to inability to work
• Pain and suffering from permanent vision impairment
• Punitive damages for drug manufacturers’ failure to disclose risks

Parker Waichman LLP is actively investigating GLP-1 drug-related blindness cases and is prepared to fight for victims who have suffered devastating, life-changing harm.

If you or a loved one lost vision after using Ozempic or Wegovy, you may be entitled to financial compensation. Call 800-968-7529 today for a free consultation with our defective drug lawyers and find out how Parker Waichman LLP can help you hold drug manufacturers accountable.